Comparison of the Effectiveness between Oral NSAIDs and Dextrose Prolotherapy in Knee Osteoarthritis

Sugiyanta Sugiyanta, Winie Septhia Dwicahyandari, Erfan Efendi, Desie Dwi Wisudanti


Non-steroidal anti-inflammatory drugs (NSAIDs) are the first treatment choice for pain relief in osteoarthritis (OA). However, known to have an 85% risk of side effects on the gastrointestinal and a 40% chance of cardiovascular complications. In addition, in certain classes of NSAIDs, the risk of chronic kidney disease increases due to long-term consumption. On the other hand, dextrose prolotherapy is a regenerative therapy. This study aimed to compare the effectiveness of oral NSAIDs with dextrose prolotherapy in knee OA based on clinical features. This study used an observational method (cross-sectional) conducted in three locations; Jember Clinic Hospital, Balung Hospital, and Harapan Mulya Kertonegoro Jenggawah Clinic from September 2021 to March 2022. Of the 75 population, 23 patients with mild to moderate knee OA were divided into two groups; 15 samples of dextrose prolotherapy and eight samples of oral NSAIDs. Data in the study showed the mean WOMAC score in the dextrose prolotherapy group was 12.4±11.7, while the oral NSAID group was 34.75±17.6. A total of 14 samples experienced a decrease in scores after switching from oral NSAIDs to dextrose prolotherapy. Bivariate analyses were performed using Mann-Whitney and Wilcoxon tests. Both statistical tests show a p=0.001 (p<0.05). Thus, this study concluded that dextrose prolotherapy was more effective than oral NSAIDs in knee OA.


Dextrose prolotherapy; knee osteoarthritis; regenerative therapy

Full Text:



Muraki S, Akune T, Nagata K, Ishimoto Y, Yoshida M, Tokimura F, et al. Association of knee osteoarthritis with onset and resolution of pain and physical functional disability: the ROAD study. Mod Rheumatol. 2014;24(6):966–73.

Perhimpunan Reumatologi Indonesia. Diagnosis dan penatalaksanaan osteoartritis. Jakarta: Perhimpunan Reumatologi Indonesia; 2014.

Rodríguez-Merchán EC, Gómez-Cardero P. Comprehensive Treatment of Knee Osteoarthritis. Basel: Springer Nature Switzerland; 2020.

Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010;69(8):1453–8.

Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on the risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–35.

Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediators Inflamm. 2013;2013:258209.

Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S22–7.

Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug-induced acute kidney injury in the community-dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256.

Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351–61.

Deeng GVY, Sekeon SAS, Warouw F. Manfaat proloterapi pada osteoartritis lutut. Ee-CliniC. 2021;9(1):250–7.

Vora A, Borg-Stein J, Nguyen RT. Regenerative injection therapy for osteoarthritis: fundamental concepts and evidence-based review. PM R. 2012;4(5 Suppl):S104–9.

Hung CY, Hsiao MY, Chang KV, Han DS, Wang TG. Comparative effectiveness of dextrose prolotherapy versus control injections and exercise in managing osteoarthritis pain: a systematic review and meta-analysis. J Pain Res. 2016;9:847–57.

Sit RWS, Wu RWK, Rabago D, Reeves KD, Chan DCC, Yip BHK, et al. Efficacy of intra-articular hypertonic dextrose (prolotherapy) for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2020;18(3):235–42.

Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:139–59.

Sathiyanarayanan S, Shankar S, Padmini SK. Usefulness of WOMAC index as a screening tool for knee osteoarthritis among patients attending a rural health care center in Tamil Nadu. IJCMPH. 2017;4(11):4290–5.

Kutlay Ş, Küçükdeveci AA, Elhan AH, Öztuna D, Koç N, Tennant A. Validation of the World Health Organization disability assessment schedule II (WHODAS-II) in patients with osteoarthritis. Rheumatol Int. 2011;31(3):339–46.

Rabago D, Zgierska A, Fortney L, Kijowski R, Mundt M, Ryan M, et al. Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: results of a single-arm uncontrolled study with 1-year follow-up. J Altern Complement Med. 2012;18(4):408–14.

Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartilage. 2019;27(11):1578–89.

Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013;39(1):1–19.

Palazzo C, Nguyen C, Lefevre-Colau MM, Rannou F, Poiraudeau S. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):134–8.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21–33.

Rabago D, Mundt M, Zgierska A, Grettie J. Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: long term outcomes. Complement Ther Med. 2015;23(3):388–95.

Hassan F, Trebinjac S, Murrell WD, Maffulli N. The effectiveness of prolotherapy in treating knee osteoarthritis in adults: a systematic review. Br Med Bull. 2017;122(1):91–108.

Gallelli L, Galasso O, Falcone D, Southworth S, Greco M, Ventura V, et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration, and signal transduction pathways in knee osteoarthritis. A randomized open-label trial. Osteoarthritis Cartilage. 2013;21(9):1400–8.

Wheaton MT, Jensen N. The ligament injury-osteoarthritis connection: the role of prolotherapy in ligament repair and the prevention of osteoarthritis. JOP. 2011;3(4):790–812.

Sekeon SAS, Sharchis S. Peran dextrosa hipertonik dalam tatalaksana proloterapi untuk osteoartritis. 2019;2(2):30–4.

Güran Ş, Çoban ZD, Karasimav Ö, Demirhan S, Karaağaç N, Örsçelik A, et al. Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apopitotic factors. Gulhane Med J. 2018;60(2):42–6.


pISSN 2301-9123 | eISSN 2460-5441

Visitor since 19 October 2016: 

View My Stats

Free counters!

Global Medical and Health Communication is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.